Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best stocks under $3 to invest in. On January 9, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) announced that it expects to achieve its previously disclosed full-year 2025 revenue guidance range of $250 to $300 million in the first full calendar year of Amtagvi sales. The company also expects Amtagvi, Iovance’s treatment regimen for advanced melanoma, will have up to $1 billion in peak sales potential. Iovance Biotherapeutics (IOVA) Gives Update on Rev ...